GNOM.L vs. URND.L
GNOM.L (Global X Genomics & Biotechnology UCITS ETF) and URND.L (Global X Uranium UCITS ETF USD Distributing) are both exchange-traded funds - GNOM.L is a Health & Biotech Equities fund tracking the Global X Genomics & Biotechnology UCITS ETF, while URND.L is a Uranium fund tracking the Solactive Global Uranium & Nuclear Components. Both are passively managed. Over the past 3 years, GNOM.L returned 4.58%/yr vs 27.93%/yr for URND.L. At a 0.34 correlation, their price movements are largely independent. GNOM.L charges 0.50%/yr vs 0.65%/yr for URND.L.
Performance
GNOM.L vs. URND.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM.L achieves a 22.10% return, which is significantly higher than URND.L's -5.27% return.
GNOM.L
- 1D
- -0.17%
- 1M
- 11.69%
- 6M
- 15.71%
- YTD
- 22.10%
- 1Y
- 62.79%
- 3Y*
- 4.58%
- 5Y*
- —
- 10Y*
- —
URND.L
- 1D
- -2.42%
- 1M
- -16.21%
- 6M
- -22.59%
- YTD
- -5.27%
- 1Y
- 9.07%
- 3Y*
- 27.93%
- 5Y*
- —
- 10Y*
- —
GNOM.L vs. URND.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
GNOM.L Global X Genomics & Biotechnology UCITS ETF | 22.10% | 19.30% | -17.99% | -5.77% | -2.52% |
URND.L Global X Uranium UCITS ETF USD Distributing | -5.27% | 58.56% | 3.00% | 32.59% | -5.08% |
Correlation
The correlation between GNOM.L and URND.L is 0.40, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.40 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Oct 28, 2022 | 0.34 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM.L vs. URND.L — Risk / Return Rank
GNOM.L
URND.L
GNOM.L vs. URND.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOM.L) and Global X Uranium UCITS ETF USD Distributing (URND.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GNOM.L | URND.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.94 | ||
| Sortino ratioReturn per unit of downside risk | +2.35 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.07 | +0.27 |
| Calmar ratioReturn relative to maximum drawdown | 3.35 | 0.28 | +3.06 |
| Martin ratioReturn relative to average drawdown | 9.16 | 0.59 | +8.58 |
Loading charts...
Drawdowns
GNOM.L vs. URND.L - Drawdown Comparison
The maximum GNOM.L drawdown since its inception was -69.32%, which is greater than URND.L's maximum drawdown of -39.03%. Use the drawdown chart below to compare losses from any high point for GNOM.L and URND.L.
Loading charts...
Drawdown Indicators
| GNOM.L | URND.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.32% | -39.03% | -30.29% |
Max Drawdown (1Y)Largest decline over 1 year | -18.91% | -32.00% | +13.09% |
Max Drawdown (3Y)Largest decline over 3 years | -44.77% | -39.03% | -5.74% |
Current DrawdownCurrent decline from peak | -37.11% | -31.31% | -5.80% |
Average DrawdownAverage peak-to-trough decline | -47.16% | -11.55% | -35.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.92% | 15.44% | -8.52% |
Volatility
GNOM.L vs. URND.L - Volatility Comparison
The current volatility for Global X Genomics & Biotechnology UCITS ETF (GNOM.L) is 8.41%, while Global X Uranium UCITS ETF USD Distributing (URND.L) has a volatility of 10.52%. This indicates that GNOM.L experiences smaller price fluctuations and is considered to be less risky than URND.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM.L | URND.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.41% | 10.52% | -2.11% |
Volatility (6M)Calculated over the trailing 6-month period | 22.18% | 34.40% | -12.22% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.87% | 50.28% | -20.41% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.11% | 39.74% | -6.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.11% | 39.74% | -6.63% |
GNOM.L vs. URND.L - Expense Ratio Comparison
GNOM.L has a 0.50% expense ratio, which is lower than URND.L's 0.65% expense ratio.
Dividends
GNOM.L vs. URND.L - Dividend Comparison
GNOM.L has not paid dividends to shareholders, while URND.L's dividend yield for the trailing twelve months is around 0.16%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
GNOM.L Global X Genomics & Biotechnology UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
URND.L Global X Uranium UCITS ETF USD Distributing | 0.16% | 0.00% | 0.93% | 0.00% | 0.02% |
Frequently Asked Questions
GNOM.L and URND.L have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, GNOM.L is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.
GNOM.L is cheaper with a 0.50% expense ratio, compared with 0.65% for URND.L.
GNOM.L is categorized as Health & Biotech Equities, while URND.L is Uranium. GNOM.L tracks Global X Genomics & Biotechnology UCITS ETF, while URND.L tracks Solactive Global Uranium & Nuclear Components. Their fees differ too: 0.50% for GNOM.L and 0.65% for URND.L.
Find the right allocation for GNOM.L and URND.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer